Change in Gait Deviation Index after anti-tumour necrosis factor-α treatment in individuals with rheumatoid arthritis: a pilot study

By Broström EW   Esbjörnsson A-C   Heideken J von   Larsson P   Wretenberg P   Iversen M  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 5, 2013-10 ,pp. : 356-361

Informa Healthcare

Access to resources Recommend Favorite

Staphylococcus aureus thymic abscesses associated with anti-tumour necrosis factor therapy

By Osiri M.   Tantawichien T.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 4, 2007-01 ,pp. : 320-321

Informa Healthcare

Access to resources Recommend Favorite

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

By Gardam M.A.   Keystone E.C.   Menzies R.   Manners S.   Skamene E.   Long R.   Vinh D.C.  

The Lancet Infectious Diseases, Vol. 3, Iss. 3, 2003-03 ,pp. : 148-155

Elsevier

Access to resources Recommend Favorite

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

By Hishitani Y   Ogata A   Shima Y   Hirano T   Ebina K   Kunugiza Y   Shi K   Narazaki M   Hagihara K   Tomita T   Yoshikawa H   Tanaka T   Kumanogoh A  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 4, 2013-08 ,pp. : 253-259

Informa Healthcare

Access to resources Recommend Favorite

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

By Kolho Kaija-Leena   Sipponen Taina  

Scandinavian Journal of Gastroenterology, Vol. 49, Iss. 4, 2014-04 ,pp. : 434-441

Informa Healthcare

Access to resources Recommend Favorite